SCHEMBL25758331

SCHEMBL25758331

O=S(=O)(NCCCN1CCC(Cc2ccccc2)CC1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
HTT P42858 1/20 0.58
KMT2A Q03164 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HTR7 P34969 5/20 0.57
SIGMAR1 Q99720 3/20 0.56
TMEM97 Q5BJF2 2/20 0.56
SLC6A2 P23975 5/20 0.51
CCR3 P51677 4/20 0.51
SLC6A3 Q01959 1/20 0.51
SLC6A4 P31645 4/20 0.50
CHRM4 P08173 1/20 0.50
MAPT P10636 1/20 0.50
HTR2A P28223 2/20 0.49
HTR1A P08908 1/20 0.49
HTR2C P28335 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25759300 0.94 PRMT6 (0.54) MEN1HTTKMT2ASMN1; SMN2SIGMAR1
SCHEMBL25758335 0.91 HTR7 (0.62) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL30376178 0.90 HTR7 (0.69) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL24070204 0.89 HTR7 (0.56) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL24069429 0.88 SLC6A2 (0.63) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL24069402 0.88 TMEM97 (0.60) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL25759699 0.88 HTR7 (0.59) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL24070124 0.87 MEN1 (0.60) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL25289791 0.85 HTR7 (0.73) MEN1HTTKMT2ASMN1; SMN2HTR7
SCHEMBL25290527 0.85 SLC6A2 (0.59) MEN1HTTKMT2ASMN1; SMN2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 CN claimed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 CN disclosed
EP-4159718-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 MEN1 2054/4885HTT 618/4885KMT2A 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.